Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Grows By 3,278.9%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 128,400 shares, a growth of 3,278.9% from the January 31st total of 3,800 shares. Based on an average trading volume of 210,100 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price target on TC Biopharm from $112.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, December 6th.

TC Biopharm Stock Down 10.1 %

TC Biopharm stock opened at $1.95 on Friday. The company has a 50 day moving average price of $6.50 and a 200 day moving average price of $37.33. TC Biopharm has a 52 week low of $1.91 and a 52 week high of $523.20.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.